PDS Biotechnology Corporation Made Big Gain
PDS Biotechnology Corporation (PDSB:NASDAQ) jumped higher at $0.99, a gain of 69.2%. On Wed, Sep 16, 2026, PDSB:NASDAQ touched a New 2-Week High of $0.99. The stock got featured on our News Catalysts scanner on Tue, Sep 15, 2026 at 04:51 PM in the 'BIOTECH' category. From Wed, Sep 02, 2026, the stock recorded 66.67% Up Days and 60.00% Green Days
The stock spiked on Thu, May 14, 2026 at $1.55 with a volume of 2M+.
About PDS Biotechnology Corporation (PDSB:NASDAQ)
Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.
Top 10 Gainers:
- Delixy Holdings Limited (DLXY:NASDAQ), 451.81%
- Q/C Technologies Inc Com Par $0.001 (QCLS:NASDAQ), 118.45%
- Antelope Enterprise Holdings Limited (AEHL:NASDAQ), 78.68%
- Zenta Group Company Limited (ZTG:NASDAQ), 75.33%
- PDS Biotechnology Corporation (PDSB:NASDAQ), 69.25%
- Tempest Therapeutics, Inc. (TPST:NASDAQ), 60.18%
- Healthy Choice Wellness Corp. (HCWC:NYSEMKT), 40.52%
- 5E Advanced Materials, Inc. (FEAM:NASDAQ), 39.68%
- Jinxin Technology Holding Company (NAMI:NASDAQ), 36.84%
- Beneficient (BENF:NASDAQ), 36.06%